Search Results

Alector is kicking off a resource realignment effort that will include a workforce reduction. The biotech expects its current cash position to last it through 2026.

In a filing with the SEC, Abbvie’s decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis (ALS) who carry a C9orf72 mutation.

Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. A

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock at a price of $25.00 per share pursuant to a registration statement on Form S-1 filed previously with the U.S. Securities and Exchange Commission (SEC).

Innovent Biologics, Inc. and Alector, Inc. jointly announced that they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody for the treatment of oncology indications in China.

Alector, Inc. announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors.

Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.

The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003.